ATRC

AtriCure Inc. (ATRC) | Rumor.io

AtriCure

ATRC

Attention (50-day avg)0%

Attention rank (50-day avg)#1,791

Bullish sentiment (50-day avg)100%

Price to earnings ratio272.9

Market capitalization3B

Earnings per share0.21

Dividend yield (TTM)—

Revenue (annual)534.5M

Net income (annual)-11.4M

Social

What share of all stock conversation is about ATRC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 2

AtriCure, Inc. (ATRC) has seen a sudden surge in demand, with a 1.18% increase in price to $48.92, and traders are watching for a potential breakout.
Analyst Mike Matson has upgraded ATRC from $45 to $64, with a rating of Buy, and increased the potential upside change from 8.01% to 30.83%.
ATRC is showing bullish momentum, with a steady surge on volume, and traders are keeping an eye on breakout levels, with some considering it an undiscovered breakout opportunity.

Generated by AI

Sentiment

Of the messages about ATRC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	97.65% +37.65
Bearish	—	—	0% 0	2.35% -37.65

Apr 28

AtriCure, Inc. ($ATRC) has seen its price target raised by multiple analysts, including Needham to $81, Oppenheimer to $75, and BTIG Research to $76.
The company's shares have responded positively to its recent financial performance, with a 6.35% increase in stock price following the release of better-than-expected first-quarter earnings and sales results.
Analysts remain bullish on AtriCure, with Needham and Oppenheimer maintaining their buy and outperform ratings, respectively, and raising their price targets to reflect the company's potential for growth.

Generated by AI

Topics

Of the messages about ATRC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	47.27%
Announcements	—	—	50%	29.09%
Earnings	—	—	0%	10%
Analysts	—	—	50%	13.64%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%

Earnings· Nov 1

AtriCure, Inc. ($ATRC) missed the Estimize EPS consensus by 4c and beat the Estimize Revenue consensus by $0.85M in FQ3.
The company reported FQ3 earnings of -24c EPS and $49.94M in revenue.
AtriCure guided FY18 EPS above consensus and revenue above consensus.

Analysts· Aug 5

AtriCure's ($ATRC) price target was raised to $120 by Canaccord Genuity and to $100 by SVB Leerink.
Oppenheimer downgraded AtriCure from Outperform to Perform, while Needham lowered its price target to $90.
Analysts at Canaccord Genuity, SVB Leerink, and Needham maintained their Buy or Outperform ratings for AtriCure, with some adjusting their price targets.

Technical Analysis· Apr 25

$ATRC is trading above its 200-day SMA, with a VWAP of $20.12.
The stock has accelerated in the past 8 days, with a near-long-term low and a 5:4 acceleration ratio.
The 30-minute moving average is at $30 million, with a 7% short-term high-pct signal.

Generated by AI

Community

Of the messages about ATRC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	7.69%	61.21%	27.01%
Newcomers	100%	92.31%	38.79%	72.99%

Regulars· Feb 22

AtriCure's Q4 2022 earnings report showed a loss, but topped revenue estimates with $88M, beating expectations of $87.77M.
Several analysts have lowered their price targets for AtriCure, including Stifel Nicolaus to $48 from $55, and Canaccord Genuity to $74 from $81.
AtriCure's Q4 2022 earnings report also showed a beat on EPS, with a loss of $0.09 compared to an expected loss of $0.18.

Newcomers· Oct 28

New investors are taking notice of AtriCure, Inc.'s stock, with some expressing regret over missing out on potential profits due to fear of trading.
The company's recent earnings report has sparked interest, with some investors highlighting the stock's strong performance and high trading volume following the announcement.
AtriCure's third quarter 2016 financial results have been met with positive reception, with the company beating expectations and posting revenue of $38.3 million.

Generated by AI

AtriCure has delivered a strong run over the past year, and the latest close at US$60.77 puts a clear spotlight on what investors are paying for its sales. The question now is how that recent performance lines up with the revenue the business is actually generating. The share price has gained 73.5% over the past year, which puts added weight on whether the current valuation can be explained by its sales base. The company’s focus on cardiac surgical devices means future growth in procedure...

4d agoYahoo! Finance Canada

Why AtriCure (ATRC) Is Back In The Spotlight

AtriCure (ATRC) has drawn fresh attention after its shares closed at US$60.77, with recent returns over the past month and past 3 months sharply outpacing many healthcare peers. Recent trading has been strong for AtriCure, with a 30-day share price return of 24.84% and a 90-day share price return of 101.36%. This feeds into a year-to-date share price gain of 54.75% and a 1-year total shareholder return of 73.48%, even though the 5-year total shareholder return is down 12.62%. Spot fresh...

4d agoYahoo Finance Singapore

AtriCure CTO Salvatore Privitera sells $271,140 in stock

5d agoInvesting.com

Atricure Insider Sold Shares Worth $271,140, According to a Recent SEC Filing

Salvatore Privitera, Chief Technical Officer, on September 23, 2026, sold 4,519 shares in Atricure (

5d agoYahoo Finance

AtriCure stock hits 52-week high at $59.91

6d agoInvesting.com

Stifel reiterates Buy rating on AtriCure stock, $65 target

12d agoInvesting.com

Also Discussed

Investors talking about ATRC also mention

#	Name	Attention
1	iShares Core Universal USD Bond ETFIUSB	0.02%new
2	PGIM Nasdaq-100 Buffer 12 ETF - JanuaryPQJA	0%0
3	First Bancorp-Southern Pines NCFBNC	0%new
4	NUVA - NuVasive, Inc.	——
5	iShares iBonds Dec 2026 Term Treasury ETFIBTG	0%0
6	iShares MSCI Europe Financials ETFEUFN	0%0
7	iShares ESG Aware MSCI EM ETFESGE	0%new
8	TMC the metals company Inc. WarrantTMCWW	0%0
9	Zimmer Biomet Holdings, Inc.ZBH	0%0
10	CONMED CorporationCNMD	0%new

AtriCure Inc.

Healthcare
Medical Instruments & Supplies

AtriCure Inc. is a medical device company that develops and sells surgical technologies for treating atrial fibrillation, managing the left atrial appendage, and controlling post-operative pain. Its portfolio includes ablation systems, left atrial appendage exclusion devices, cryoablation products, and related surgical instruments used in cardiac, thoracic, and electrophysiology procedures. AtriCure’s products are designed for use by cardiothoracic surgeons, electrophysiologists, and medical centers that perform open, minimally invasive, and hybrid cardiac surgeries. The company serves healthcare providers in the United States and international markets, supporting procedure workflows in hospitals and specialized surgical settings. Founded in 2000 and headquartered in Mason, Ohio, AtriCure focuses on device-based therapies that address important needs in rhythm management and surgical pain control.

Website

Location

7555 Innovation Way

Mason, OH, 45040

United States

Social

What share of all stock conversation is about ATRC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 2

AtriCure, Inc. (ATRC) has seen a sudden surge in demand, with a 1.18% increase in price to $48.92, and traders are watching for a potential breakout.
Analyst Mike Matson has upgraded ATRC from $45 to $64, with a rating of Buy, and increased the potential upside change from 8.01% to 30.83%.
ATRC is showing bullish momentum, with a steady surge on volume, and traders are keeping an eye on breakout levels, with some considering it an undiscovered breakout opportunity.

Generated by AI

Sentiment

Of the messages about ATRC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	97.65% +37.65
Bearish	—	—	0% 0	2.35% -37.65

Apr 28

AtriCure, Inc. ($ATRC) has seen its price target raised by multiple analysts, including Needham to $81, Oppenheimer to $75, and BTIG Research to $76.
The company's shares have responded positively to its recent financial performance, with a 6.35% increase in stock price following the release of better-than-expected first-quarter earnings and sales results.
Analysts remain bullish on AtriCure, with Needham and Oppenheimer maintaining their buy and outperform ratings, respectively, and raising their price targets to reflect the company's potential for growth.

Generated by AI

Topics

Of the messages about ATRC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	47.27%
Announcements	—	—	50%	29.09%
Earnings	—	—	0%	10%
Analysts	—	—	50%	13.64%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%

Earnings· Nov 1

AtriCure, Inc. ($ATRC) missed the Estimize EPS consensus by 4c and beat the Estimize Revenue consensus by $0.85M in FQ3.
The company reported FQ3 earnings of -24c EPS and $49.94M in revenue.
AtriCure guided FY18 EPS above consensus and revenue above consensus.

Analysts· Aug 5

AtriCure's ($ATRC) price target was raised to $120 by Canaccord Genuity and to $100 by SVB Leerink.
Oppenheimer downgraded AtriCure from Outperform to Perform, while Needham lowered its price target to $90.
Analysts at Canaccord Genuity, SVB Leerink, and Needham maintained their Buy or Outperform ratings for AtriCure, with some adjusting their price targets.

Technical Analysis· Apr 25

$ATRC is trading above its 200-day SMA, with a VWAP of $20.12.
The stock has accelerated in the past 8 days, with a near-long-term low and a 5:4 acceleration ratio.
The 30-minute moving average is at $30 million, with a 7% short-term high-pct signal.

Generated by AI

Community

Of the messages about ATRC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	7.69%	61.21%	27.01%
Newcomers	100%	92.31%	38.79%	72.99%

Regulars· Feb 22

AtriCure's Q4 2022 earnings report showed a loss, but topped revenue estimates with $88M, beating expectations of $87.77M.
Several analysts have lowered their price targets for AtriCure, including Stifel Nicolaus to $48 from $55, and Canaccord Genuity to $74 from $81.
AtriCure's Q4 2022 earnings report also showed a beat on EPS, with a loss of $0.09 compared to an expected loss of $0.18.

Newcomers· Oct 28

New investors are taking notice of AtriCure, Inc.'s stock, with some expressing regret over missing out on potential profits due to fear of trading.
The company's recent earnings report has sparked interest, with some investors highlighting the stock's strong performance and high trading volume following the announcement.
AtriCure's third quarter 2016 financial results have been met with positive reception, with the company beating expectations and posting revenue of $38.3 million.

Generated by AI

AtriCure

Social

Sep 2

Apr 28

Earnings· Nov 1

Analysts· Aug 5

Technical Analysis· Apr 25

Regulars· Feb 22

Newcomers· Oct 28

AtriCure (ATRC) Stock Looks Rich Against Its Sales Base

Why AtriCure (ATRC) Is Back In The Spotlight

AtriCure CTO Salvatore Privitera sells $271,140 in stock

Atricure Insider Sold Shares Worth $271,140, According to a Recent SEC Filing

AtriCure stock hits 52-week high at $59.91

Stifel reiterates Buy rating on AtriCure stock, $65 target

Also Discussed

AtriCure Inc.

Company Information

Location

AtriCure (ATRC) Stock Looks Rich Against Its Sales Base

Why AtriCure (ATRC) Is Back In The Spotlight

AtriCure CTO Salvatore Privitera sells $271,140 in stock

Atricure Insider Sold Shares Worth $271,140, According to a Recent SEC Filing

AtriCure stock hits 52-week high at $59.91

Stifel reiterates Buy rating on AtriCure stock, $65 target

Also Discussed

Social

Sep 2

Apr 28

Earnings· Nov 1

Analysts· Aug 5

Technical Analysis· Apr 25

Regulars· Feb 22

Newcomers· Oct 28